Its novel mechanism allows the peptide to act as an agonist for both GLP-1 and GIP receptors
That is why your history matters, including family endocrine cancer history
Dietary modification and careful dose adjustment minimize overlap between the two conditions
Human studies have also provided evidence for cardioprotective functions of GLP-1 analogs and DPP-4 inhibitors in both diabetics and non-diabetics, although larger, randomized trials are still required
When initial therapy proves insufficient, treatment escalation includes: Biologic DMARDs targeting specific inflammatory pathways (TNF inhibitors, IL-6 inhibitors, T-cell costimulation blockers, B-cell depleting agents) Targeted synthetic DMARDs such as JAK inhibitors (tofacitinib, baricitinib, upadacitinib), which carry FDA boxed warnings for serious cardiovascular events, malignancy, and thrombosis [24] [25] Combination DMARD therapy Short-term glucocorticoids for symptom control during treatment initiation Before starting biologic or targeted synthetic DMARDs, screening for tuberculosis and hepatitis B is recommended, along with appropriate vaccinations according to ACR guidelines
Some studies showed prevention benefits even in the absence of metabolic changes.[ref][ref] Cardiovascular health: Several clinical trials now show GLP-1 RA benefits for heart health that go beyond just weight loss or diabetes control
